Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1693-1700

  Oldenburg, Rogier A ^a,c   Kroeze Jansema, Karin ^a   Meijers Heijboer, Hanne ^c   Van Asperen, Cristi J ^a   Hoogerbrugge, Nicoline ^d   Van Leeuwen, Inge ^b   Vasen, Hans F A ^b   Cleton Jansen, Anne Marie ^a   Kraan, Jaennelle ^a   Houwing Duistermaat, Jeanine J ^a   Morreau, Hans ^a   Cornelisse, Cees J ^a   Devilee, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Foundation for the Detection of Hereditary Tumors   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN BCL 2;

ARTICLE; BREAST TUMOR; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 2; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 3; CHROMOSOME 6; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 22; CLUSTER ANALYSIS; FAMILY HEALTH; FEMALE; GENETIC LINKAGE; GENOME, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LINKAGE (GENETICS); LOD SCORE; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645658386     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2230     Document Type: Article

References (55)

1. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
2. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9.
3. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
4. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76.
5. Seitz S, Rohde K, Bender E, et al. Strong indication for a breast cancer susceptibility gene on chromosome 8p12-22: linkage analysis in German breast cancer families. Oncogene 1997;14:741-3.
6. Kainu T, Juo SH, Desper R, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A 2000;97:9603-8.
7. Rahman N, Teare MD, Seal S, et al. Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-22. Oncogene 2000:19:4170-3.
8. Thompson D, Szabo CI, Mangion J, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002;99:827-31.
9. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-14.
10. van Beers EH, Van Welsem T, Wessels LF, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005;65:822-7.
11. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93-100.
12. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
13. Van't Veer LJ, Dai HY, Van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
14. Hedenfalk I, Ringner M, Ben Dor A, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 2003;100:2532-7.
15. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7.
16. Hogervorst F, Cornelis R, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
17. Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours. J Med Genet 2004;41:e31.
18. Petrij-Bosch A, Peelen T, Van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341:5.
19. Korkko J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA 1998;95:1681-5.
20. Hogervorst FBL, Nederlof PM, Gille JJP, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003:63:1449-53.
21. Tumours of the breast. In: Tavassoli FA, Devilee P, editors. World Health Organization: Tumours of the breast and female genital organs. Lyon: IARC Press: 2003.
22. Ghebranious N, Vaske D, Yu A, Zhao C, Marth G, Weber JL. STRP screening sets for the human genome at 5 cM density. BMC Genomics 2003;4:6.
23. Gupta PK, Sahota A, Boyadjiev SA, et al. High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Res 1997;57:1188-93.
24. Tischfield JA. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am J Hum Genet 1997;61:995-9.
25. Cleton-Jansen AM, Callen DF, Seshadri R, et al. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 2001;61:1171-7.
26. Devilee P, Cleton-Jansen AM, Cornelisse CJ. Ever since Knudson.Trends Genet 2001;17:569-73.
27. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
28. Houwing-Duistermaat JJ, Derkx BH, Rosendaal FR, Van Houwelingen HC. Testing familial aggregation. Biometrics 1995;511292-301.
29. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347-63.
30. Claus EB, Risch N, Douglas W. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
31. Easton D, Bishop D, Ford D, Crockford G; Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52:678-701.
32. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002;30:97-101.
33. Lakhani SR, Gusterson BA, Breast Cancer Linkage Consortium, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
34. Abd El-Rehim DM, Finder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
35. Miller BJ, Wang D, Krahe R, Wright FA. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 2003;73:748-67.
36. Tirkkonen M, Johansson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
37. Nathanson KL, Weber BL. Other breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 2001;10:715-20.
38. Tirkkonen M, Kainu T, Loman N, et al. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999;24:56-61.
39. Janne PA, Li C, Zhao XJ, et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004;23:2716-26.
40. Knudson AG. Hereditary cancer: theme and variations. J Clin Oncol 1997;15:3280-7.
41. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-9.
42. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
43. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
44. Sorlie T. Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
45. Bibikova M, Talantov D, Chudin E, et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 2004;165:1799-807.
46. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers Clin Cancer Res 2004;10:2473-81.
47. Lakhani SR, Van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
48. Foulkes WD, Stefansson IM, Chappuis PO, et al Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
49. Maguire P, Holmberg K, Kost-Alimova M, Imreh S, Skoog L, Lindblom A. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2 - 12. Int J Mol Med 2005;16:135-41
50. Gronwald J, Jauch A, Cybulski C, et al. Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer 2005;114:230-6.
51. Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83.
52. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 2003;25:190-202.
53. Cui J, Antoniou AC, Dite GS, et al. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 2001;68:420-31.
54. Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet 2003;112:434-5.
55. Meijers-Heijboer H, Van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.